Posters
Design Of Total Anti-Vegf Assay Provides Simple Data Interpretation Of Anti-Vegf Therapeutic Study
Vascular Endothelial Growth Factor (VEGF) is an angiogenic factor associated with an array of diseases, including several cancers and retinopathy, making this protein both a…
Development of a 10 color flow cytometric assay to assess binding of a monoclonal antibody (VB421) against IGF 1R in Peripheral Blood Mononuclear Cells (PBMCs) from patients with Thyroid Eye Disease
Thyroid Eye Disease ( also known as Graves’ ophthalmopathy, is a debilitating autoimmune disorder that occurs in patients with Graves’ Disease in which inflammation in…
Determination of Mifepristone in Human Plasma by Automated On-Line SPE Combined with MS/MS
Mifepristone is a synthetic steroid compound that has been studied in Phase II clinical trials for many medical uses, including: oral contraception, uterine fibroids, endometriosis
Embryo-Fetal Developmental Toxicokinetic Study of CBX129801, a Bio-active C-peptide for Potential Replacement Therapy in Type 1 Diabetic Nephropathy, in Rats and Rabbits After Subcutaneous Injections
To evaluate the maternal toxicokinetics and fetal exposures of CBX129801 in studies which assessed the developmental toxicity, after subcutaneous injection for 4 doses to pregnant…
Phase 1 Pharmacokinetic (PK) Assessment of ATI-1123, a Novel Human Serum Albumin-Stabilized Nanoparticle Docetaxel Liposomal Formulation, in Patients with Advanced Solid Malignancies
ATI-1123, a novel nanoparticle docetaxel liposomal formulation, is being investigated in patients (pts) with advanced solid malignancies. ATI-1123 is expected to reduce hypersensitivity reactions, have…
Toxicokinetics and Immunogenicity of CBX129801, a Pegylated C-Peptide Drug for Type 1 Diabetes Replacement Therapy, in Sprague Dawley Rats
To assess toxicokinetics (TK) and immunogenicity of CBX129801 in rats after subcutaneous (SC) injections for 4 weeks (5 doses) with 4-week recovery period.
Toxicokinetics of ETI-385 and its Components ETI-382 and ETI-383, a Serotonin 5-HT1A Receptor Agonist for Treatment of Nausea and Vomiting, Following Subcutaneous Injection of ETI-385 to CD-1 Mice and Beagle Dogs
To assess the toxicokinetics (TK) of ETI-382 and ETI-383 in CD-1 mice and Beagle dogs following subcutaneous injection of ETI-385. ETI-385, an 8-to-1 fixed ratio…
Toxicokinetics of CBX129801, a Bio-active C-Peptide for Potential Replacement Therapy in Type 1 Diabetic Neuropathy, in Rats and Monkeys After Subcutaneous Injections
To assess the toxicokinetics (TK) of CBX129801 in rats and monkeys following once weekly subcutaneous injection for 5 doses
Toxicokinetics of CBX129801, a Bio-active C-Peptide for Potential Replacement Therapy in Type 1 Diabetic Peripheral Neuropathy, Following Subcutaneous Injection of CBX129801 in Monkeys in a 9-Month Study with a 7-Week Recovery Period
To assess the toxicokinetics (TK) of CBX129801 in Sprague Dawley Rats following once weekly subcutaneous injection for 26 doses.
Pharmacokinetics of AC220 and its Active Metabolite AC886, a FLT-3 Inhibitor, Following Sequential Oral Dose Escalation to Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
AC220, a FLT-3 inhibitor, is being investigated for the treatment of Acute Myeloid Leukemia (AML). The objective of this study was to investigate the safety,…